Mergers & Acquisitions
M&A: Medtech makers use acquisitions to fill niches
Medical device companies opted to fill in their portfolios with niche acquisitions during the 1st quarter, rather than venturing into new treatment areas or looking to diversify, according to a report by a healthcare investment bank.
Is Boston Scientific’s peripherals buy bad news for Cardiovascular Systems?
Boston Scientific’s (NYSE:BSX) $415 million acquisition of Bayer AG’s interventional unit is a strong move for the company, but it may bode ill for other peripheral players.
Boston Scientific bolsters peripheral business with $415M Bayer buy
Boston Scientific (NYSE:BSX) said it agreed to acquire Bayer AG’s interventional unit for $415 million, in a move to significantly bolster its own $200 million peripheral interventions business.
Steris closes $165M IMS buy, takes $20.5M charge for restructuring in Q4
M&A: Z-Medica nabs TAUREON’S Novacol hemostatic products
Connecticut-based Z-Medical announced this month that it acquired the Novacol resorbable hemostatic product line from rival TAUREON, headquartered in The Netherlands.
TAUREON said that it hopes to focus more on its core businesses, giving over the Novacol line to Z-Medica and its vast distribution network. The companies did not disclose the terms of the deal.
Valeant pledges to sweeten $47B bid for Allergan
GE’s new cybersecurity buy includes medical devices | MassDevice.com On Call
Allergan board spurns Valeant’s $47B offer
Cardinal Health closes $320M AccessClosure buy
Cardinal Health (NYSE:CAH) said today that it closed its $320 million all-cash acquisition of AccessClosure and its Mynx extravascular closure technology.
The Mynx biodegradable sealant products are designed to close off the femoral artery and then dissolve within 30 days.